Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Martek/Abbott exclusive supply deal

This article was originally published in The Tan Sheet

Executive Summary

Martek Biosciences will serve as exclusive worldwide supplier of DHA and ARA for Abbott Nutrition's infant formula products, including Similac Advance, under a new, long-term supply agreement announced Oct. 8. Abbott signed a 25-year, non-exclusive supply agreement with Martek in 2000 that will remain in effect (1"The Tan Sheet" Sept. 29, 2003, p. 14). The new deal provides for a 10-year term, though Abbott can terminate as of January 2012. Martek's life'sDHA and life'sARA ingredients are used in more than 95% of U.S. infant formulas...

You may also be interested in...



Martek Pursues Cheaper DHA Cost Structure To Give Ingredient Wider Appeal

Martek Biosciences is working toward substantially lowering the cost of making docosahexaenoic acid (DHA) through a business venture with a genetics seed company

QUOTED. 29 September 2020. Phil Brown.

ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.

COVID-19 Vaccines: HHS Advisory Committee Urges ‘Great Caution’ On Use Of EUA

Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel